Unity Biotechnology (NASDAQ:UBX) Given New $6.00 Price Target at Citigroup

Unity Biotechnology (NASDAQ:UBX – Get Rating) had its price target upped by Citigroup from $5.00 to $6.00 in a report published on Friday, The Fly reports. Several other equities analysts also recently commented on the company. Wedbush decreased their target price on Unity Biotechnology from $35.00 to $5.00 and set an outperform rating on the […]

Related Keywords

Blackrock ,United Kingdom General ,United Kingdom ,Jan Van Deursen ,Judith Campisi ,Nathaniel Eames David ,Blackrock Inc ,Unity Biotechnology Inc ,Arete Wealth Advisors ,Unity Biotechnology Company Profile ,Citigroup ,Geode Capital Management ,Unity Biotechnology ,Get Rating ,Wealth Advisors ,Street Corp ,Capital Management ,Sigma Investments ,Daohong Zhou ,South San Francisco ,Unity Biotechnology Daily ,Nasdaq Ubx ,Subx ,Medical ,Boost Price Target ,Citigroup Inc ,